Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease.
Yan Duan, Hui Li, Dinghua Luo, Jun Jiang, Bin Liu, Gang Li
Author Information
Yan Duan: Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, Sichuan, China; Sichuan Clinical Research Center for Birth Defects, China.
Hui Li: Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, Sichuan, China; Sichuan Clinical Research Center for Birth Defects, China.
Dinghua Luo: Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, Sichuan, China; Sichuan Clinical Research Center for Birth Defects, China.
Jun Jiang: Department of General Surgery (Thyroid Surgery), the Affiliated Hospital of Southwest Medical University, China; Metabolic Vascular Diseases Key Laboratory of Sichuan Province, China.
Bin Liu: Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, Sichuan, China; Sichuan Clinical Research Center for Birth Defects, China. Electronic address: lblyfy@126.com.
Gang Li: Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, Sichuan, China; Sichuan Clinical Research Center for Birth Defects, China. Electronic address: 479719170@qq.com.
BACKGROUND: This study aimed to evaluate serum IL-41 levels in IVIG resistance and CALs, and to elucidate the relationship between IL-41 and Kawasaki disease (KD)-related clinical parameters. METHODS: 93 children with KD were collected. Baseline clinical data were obtained by physical examination. Serum IL-41 levels were detected with an enzyme-linked immunosorbent assay. The correlations between IL-41 and the clinical parameter of KD were performed by Spearman correlation coefficient. Receiver operating characteristic curve analysis was performed to assess the predictive ability of IL-41 for IVIG resistance and CALs. RESULTS: Serum IL-41 levels were significantly increased in the IVIG resistance group compared with the response group, and serum IL-41 levels in the CALs group were higher than those in the non-CALs group. Serum IL-41 levels were positively correlated with erythrocyte sedimentation rate, C-reactive protein and C-reactive protein/albumin ratio, but negatively correlated with albumin. Serum IL-41 levels was an independent risk factor for CALs, and total fever days and neutrophil-to-lymphocyte ratio (NLR) were independent predictors for IVIG resistance. The area under the curve (AUC) value for serum IL-41 to predict IVIG resistance was 0.73, yielding a sensitivity of 54.55% and a specificity of 81.71%. The AUC of serum IL-41 was 0.712, with a sensitivity of 63.16% and a specificity of 72.97% for predicting CALs. IL-41 was not inferior to NLR in predicting IVIG resistance (z = 0.282, p = 0.7783). CONCLUSIONS: Serum IL-41 was increased in IVIG resistance and CALs. Serum IL-41 might be a new potential biomarker for IVIG resistance and CALs.
